Shares of Axovant Sciences Ltd (NASDAQ:AXON) have received an average recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.93.
A number of equities analysts have commented on the company. ValuEngine raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Wednesday, January 31st. Cowen reissued a “hold” rating on shares of Axovant Sciences in a research note on Tuesday, February 13th. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Axovant Sciences in a research report on Friday, December 1st. Finally, BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd.
Axovant Sciences (NASDAQ:AXON) opened at $1.51 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.58 and a current ratio of 4.58. The stock has a market capitalization of $157.37, a PE ratio of -0.66 and a beta of -0.46. Axovant Sciences has a 12 month low of $1.40 and a 12 month high of $27.98.
Hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in Axovant Sciences by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 3,184 shares during the last quarter. California State Teachers Retirement System increased its holdings in Axovant Sciences by 10.0% in the second quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after purchasing an additional 4,800 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in Axovant Sciences in the third quarter valued at about $101,000. Cubist Systematic Strategies LLC bought a new stake in Axovant Sciences in the third quarter valued at about $117,000. Finally, Wells Fargo & Company MN increased its holdings in Axovant Sciences by 135.6% in the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock valued at $369,000 after purchasing an additional 30,905 shares during the last quarter. Institutional investors own 93.12% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Receives Consensus Recommendation of “Hold” from Analysts” was first published by Week Herald and is owned by of Week Herald. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://weekherald.com/2018/03/17/axovant-sciences-ltd-axon-receives-consensus-recommendation-of-hold-from-analysts-2.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.